California State Teachers Retirement System lifted its holdings in Immune Design Corp (NASDAQ:IMDZ) by 82.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 50,518 shares of the biotechnology company’s stock after buying an additional 22,799 shares during the quarter. California State Teachers Retirement System owned approximately 0.11% of Immune Design worth $197,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also modified their holdings of the company. Schwab Charles Investment Management Inc. raised its holdings in shares of Immune Design by 59.7% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 54,543 shares of the biotechnology company’s stock worth $213,000 after buying an additional 20,400 shares during the period. Deutsche Bank AG raised its holdings in shares of Immune Design by 121.2% in the fourth quarter. Deutsche Bank AG now owns 72,278 shares of the biotechnology company’s stock worth $280,000 after buying an additional 39,608 shares during the period. Two Sigma Advisers LP purchased a new stake in shares of Immune Design in the fourth quarter worth approximately $449,000. Bank of New York Mellon Corp raised its holdings in shares of Immune Design by 68.1% in the fourth quarter. Bank of New York Mellon Corp now owns 122,073 shares of the biotechnology company’s stock worth $476,000 after buying an additional 49,464 shares during the period. Finally, Two Sigma Investments LP raised its holdings in shares of Immune Design by 1,222.6% in the fourth quarter. Two Sigma Investments LP now owns 217,917 shares of the biotechnology company’s stock worth $850,000 after buying an additional 201,441 shares during the period. Hedge funds and other institutional investors own 53.78% of the company’s stock.
Several research analysts have commented on the company. Zacks Investment Research downgraded Immune Design from a “buy” rating to a “hold” rating in a report on Monday, March 12th. Jefferies Group restated a “buy” rating and set a $8.00 price objective on shares of Immune Design in a report on Thursday, March 15th. Finally, Cowen restated a “buy” rating on shares of Immune Design in a report on Monday, December 11th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $10.63.
IMDZ opened at $3.20 on Tuesday. The firm has a market cap of $151.59, a price-to-earnings ratio of -1.83 and a beta of 1.89. Immune Design Corp has a 52 week low of $2.80 and a 52 week high of $13.05.
Immune Design (NASDAQ:IMDZ) last released its quarterly earnings data on Wednesday, March 14th. The biotechnology company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.10. The company had revenue of $0.49 million for the quarter, compared to the consensus estimate of $0.81 million. Immune Design had a negative return on equity of 57.56% and a negative net margin of 720.81%. equities analysts predict that Immune Design Corp will post -1.33 earnings per share for the current fiscal year.
WARNING: This story was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another domain, it was stolen and reposted in violation of United States and international trademark and copyright laws. The original version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/10/immune-design-corp-imdz-stake-raised-by-california-state-teachers-retirement-system.html.
Immune Design Profile
Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.
Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with MarketBeat.com's FREE daily email newsletter.